– USA, CA – Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, announced the appointment of Dr. Laurence Reid (Ph.D.) to its Board of Directors.
About Dr. Laurence Reid
Dr. Laurence Reid is an entrepreneur, company builder, and biotech executive, leveraging his experience as an advisor to growing biotech companies. He serves as chairperson of the board of directors of Broken String Biosciences Ltd. and on the boards of directors of KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) and several other private biotechnology companies.
Previously, Dr. Laurence Reid was president and CEO of Decibel Therapeutics, Inc., until its acquisition by Regeneron Pharmaceuticals, Inc. in 2023, and CEO of Warp Drive Bio, LLC until its merger with Revolution Medicines, Inc. in 2018. He has also served as an entrepreneur in residence at Third Rock Ventures LLC.
Before that, Dr. Laurence Reid served as CBO of Alnylam Pharmaceuticals, Inc., and as GM of Millennium Europe at Millennium Pharmaceuticals, Inc., which is now part of Takeda Pharmaceutical Company Limited.
Dr. Laurence Reid received a B.A. in natural sciences from Cambridge University and a Ph.D. in biochemistry from King’s College, London University.
About Metagenomi
Metagenomi is a precision gene editing company leveraging the power of artificial intelligence and machine learning to develop the next generation of potentially curative genome editing therapeutics. Its metagenomics-derived gene editing toolbox has analyzed over 7.4 billion proteins and has the potential to target any type of genetic mutation across the entire human genome. The Company’s innovative and comprehensive platform has full-spectrum gene editing, with technologies ranging from ultra-small nucleases and base editors to large gene integrations using CRISPR-associated transposase and RNA-Mediated Integration Systems. The Company’s lead, wholly-owned development program in Hemophilia A is a potentially curative therapy designed to provide life-long protection from bleeding events and joint damage in adults and children. The Company has additional wholly-owned assets in its pipeline for secreted protein deficiencies and partnered assets for cardiometabolic diseases.
For more: https://metagenomi.co/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.